Ocular and Upstream drop on less-than-wow data; Compass rallies on second Phase III win for psilocybin

Ocular and Upstream both saw share price losses this week despite positive clinical data, while Compass got a boost from a second Phase III win for its synthetic psilocybin in treatment-resistant depression.

Ocular Therapeutix Inc. (NASDAQ:OCUL) said that its VEGF1/2/3 inhibitor, Axpaxli axitinib, bested aflibercept in the head-to-head Phase III SOL-1 trial to treat wet age-related macular degeneration (AMD), with 74.1% of patients in the Axpaxli arm maintaining visual acuity versus 55.8% in the aflibercept arm by 36 weeks (p<0.0006). The study also met its secondary endpoint of 52 week durability with 65.9% of patients maintaining visual acuity on AXPAXLI compared to 44.2% aflibercept...